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Background
Onset of action is recognized as an important pharma-
cologic property of allergic rhinitis medications and can
be reliably determined under the controlled conditions
of the Environmental Exposure Unit (EEU).
Objective
To evaluate the onset of action of loratadine/montelu-
kast (10 mg/10 mg) versus placebo in subjects with rag-
weed-induced seasonal allergic rhinitis (SAR).
Methods
A single-center, double-blind, parallel-group study of
ragweed-sensitive allergic rhinitis subjects (N=310), per-
formed in the EEU. Subjects were exposed to ragweed
pollen in the EEU and symptoms were recorded at 30,
60, 90, and 120 minutes prior to a single dose of lorata-
dine/montelukast or placebo. After dosing, symptoms
were recorded for 4 hours - at 15-minute intervals for
the first 2 hours and 30-minute intervals for the final 2
hours. The primary endpoint was the time to onset of
action for loratadine/montelukast, defined as the first
time point at which the mean change from baseline in
total symptom score (TSS) for loratadine/montelukast
became and remained significantly better than placebo.
Secondary endpoints included nasal congestion scores
and peak nasal inspiratory flow (PNIF).
Results
The onset of action of loratadine/montelukast for TSS
was 1 hour 15 minutes (p=0.005 versus placebo). Lorata-
dine/montelukast reduced nasal congestion as indicated
by significant improvements in both the nasal conges-
tion score (p=0.011) and PNIF measurements (p=0.007)
within 1 hour 15 minutes post dose. The incidence of
treatment-emergent adverse events was similar between
groups.
Conclusion
The onset of action following treatment with loratadine/
montelukast was 1 hour 15 minutes for TSS, as well as
for nasal congestion. Loratadine/montelukast was well
tolerated.
Acknowledgements
Funding for this study was provided by Schering-Plough/Merck
Pharmaceuticals.
Author details
1Department of Medicine, Queen’s University and Division of Allergy &
Immunology, Kingston General Hospital, Kingston, ON, Canada .
2Schering-
Plough Research Institute, Kenilworth, NJ, USA.
Published: 12 May 2010
doi:10.1186/1710-1492-6-S1-P29
Cite this article as: Day et al.: Onset of action of loratadine/montelukast
combination in subjects with seasonal allergic rhinitis in the
environmental exposure unit. Allergy, Asthma & Clinical Immunology 2010
6(Suppl 1):P29.
* Correspondence: dayj@kgh.kari.net
1Department of Medicine, Queen’s University and Division of Allergy &
Immunology, Kingston General Hospital, Kingston, ON, Canada
Day et al. Allergy, Asthma & Clinical Immunology 2010, 6(Suppl 1):P29
http://www.aacijournal.com/content/6/S1/P29 ALLERGY, ASTHMA & CLINICAL 
IMMUNOLOGY
© 2010 Day et al; licensee BioMed Central Ltd.